Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: The multiethnic cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 3, 2013, Pages 337-347

  Conroy, Shannon M ^a   Maskarinec, Gertraud ^b   Morimoto, Yukiko ^b   Franke, Adrian A ^b   Cooney, Robert V ^c   Wilkens, Lynne R ^b   Goodman, Marc T ^b   Hernadez, Brenda Y ^b   Marchand, Loïc Le ^b   Henderson, Brian E ^d   Kolonel, Laurence N ^b  

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICAN; AGED; ARTICLE; ASIAN AMERICAN; AUTOANALYZER; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR LYMPHOMA; HISPANIC; HUMAN; LARGE CELL LYMPHOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OBESITY; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; T CELL LYMPHOMA;

ADIPOSITY; AGED; CASE-CONTROL STUDIES; CYTOKINES; ETHNIC GROUPS; FEMALE; HUMANS; INFLAMMATION; LEPTIN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876519447     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0947     Document Type: Article

References (52)

1. Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90-8.
2. Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16:401-4. (Pubitemid 46548640)
3. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16: 405-8. (Pubitemid 46548641)
4. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44. (Pubitemid 41640845)
5. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38.
6. Vendrame E, Martinez-Maza O. Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res 2011;10:113-9.
7. Chiu BC, Weisenburger DD. An update of the epidemiology of non- Hodgkin's lymphoma. Clin Lymphoma 2003;4:161-8. (Pubitemid 38128680)
8. Mori T, Takada R, Watanabe R, Okamoto S, Ikeda Y. T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother 2001; 50:566-8. (Pubitemid 34028290)
9. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:532-62. (Pubitemid 26366537)
10. Eisenstein EM, Williams CB. The T(reg)/Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res 2009;65:26R-31R.
11. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
12. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009;69:5522-30.
13. Bel Hadj Jard B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, Ajimi S, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 2007;78:117-22. (Pubitemid 46058873)
14. Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011;117:585-90.
15. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101-8. (Pubitemid 43726819)
16. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007;28:704-12. (Pubitemid 46523368)
17. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38. (Pubitemid 43025390)
18. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006;66:9771-80. (Pubitemid 44623679)
19. Willett EV, Skibola CF, Adamson P, Skibola DR, Morgan GJ, Smith MT, et al. Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 2005;93:811-6. (Pubitemid 41486443)
20. Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, Reding DJ, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 2011;71:4898-907.
21. Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control 2010;21:1323-33.
22. Saberi HF, Krop EJ, Scoccianti C, Krogh V, Palli D, Panico S, et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2010;19:1577-84.
23. Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev 2001;2:131-40. (Pubitemid 33755922)
24. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin's lymphoma: a meta-analysis. Int J Cancer 2007;121:1564-70. (Pubitemid 47328717)
25. Willett EV, Morton LM, Hartge P, Becker N, Bernstein L, Boffetta P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer 2008;122:2062-70. (Pubitemid 351441197)
26. Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011;47:2422-30.
27. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004;4:371-9. (Pubitemid 38649279)
28. Lam QL, Wang S, Ko OK, Kincade PW, Lu L. Leptin signaling maintains B-cell homeostasis via induction of Bcl-2 and Cyclin D1. Proc Natl Acad Sci U S A 2010;107:13812-7.
29. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96: 1723-32. (Pubitemid 30661055)
30. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004;323:630-5. (Pubitemid 39221142)
31. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5: 749-59. (Pubitemid 41400849)
32. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007;67:5042-54. (Pubitemid 46910215)
33. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000;151:346-57. (Pubitemid 30463612)
34. Park SY, Wilkens LR, Henning SM, Le ML, Gao K, Goodman MT, et al. Circulating fatty acids and prostate cancer risk in a nested case- control study: the Multiethnic Cohort. Cancer Causes Control 2009;20:211-23.
35. Hatcher L. A step-by-step approach to using the SAS system for factor analysis and structural equation modeling. Cary, NC: SAS Publishing; 1994.
36. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-37. (Pubitemid 19030705)
37. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004;15: 61-76. (Pubitemid 38121291)
38. Epeldegui M, Widney DP, Martinez-Maza O. Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 2006;18:444-8. (Pubitemid 44199839)
39. Czarneski J, Lin YC, Chong S, McCarthy B, Fernandes H, Parker G, et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 2004;18:597-606. (Pubitemid 38425876)
40. Guney N, Soydinc HO, Basaran M, Bavbek S, Derin D, Camlica H, et al. Serum levels of interleukin-6 and interleukin-10 in Turkish patientswith aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev 2009;10:669-74.
41. Pamuk GE, Turgut B, Demir M, Vural O. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res 2006;25:537-41. (Pubitemid 46166768)
42. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, et al. Plasma TNF-alpha and IL-10 levelbased prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz) 2010;58:131-41.
43. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003;109:119-29. (Pubitemid 37338618)
44. Emilie D, Touitou R, Raphael M, Peuchmaur M, Devergnee O, Rea D, et al. In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. Eur J Immunol 1992;22:2937-42.
45. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499-505. (Pubitemid 27011386)
46. Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, et al. Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2004;13: 779-86. (Pubitemid 38737867)
47. Thomas T, Burguera B, Melton LJ III, Atkinson EJ, O'Fallon WM, Riggs BL, et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 2000; 49:1278-84.
48. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70. (Pubitemid 28485436)
49. Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med 2012;33:35-45.
50. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33:547-94.
51. Petridou ET, Sergentanis TN, Dessypris N, Vlachantoni IT, Tseleni- Balafouta S, Pourtsidis A, et al. Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: a nationwide case-control study. J Clin Oncol 2009;27:5049-55.
52. Alberti L, Gilardini L, Girola A, Moro M, Cavagnini F, Invitti C. Adiponectin receptors gene expression in lymphocytes of obese and anorexic patients. Diabetes Obes Metab 2007;9:344-9. (Pubitemid 46502053)